<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02970318</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-CL-309</org_study_id>
    <nct_id>NCT02970318</nct_id>
  </id_info>
  <brief_title>A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL</brief_title>
  <official_title>A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerta Pharma BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acerta Pharma BV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in
      combination with idelalisib or bendamustine in previously treated subjects with chronic
      lymphocytic leukemia (CLL).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IRC-assessed progression-free survival (PFS) in Arm A compared to Arm B</measure>
    <time_frame>48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed progression-free survival (PFS) in Arm A compared to Arm B</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator and IRC-assessed overall response rate (ORR) in Arm A compared to Arm B</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) in Arm A compared to Arm B</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes (PROs) in Arm A compared to Arm B</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator and IRC-assessed duration of response (DOR) in Arm A compared to Arm B</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment (TTNT) in Arm A compared to Arm B</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">306</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Acalabrutinib (ACP-196)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acalabrutinib (ACP-196) Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab Plus Idelalisib or Bendamustine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acalabrutinib (ACP-196)</intervention_name>
    <arm_group_label>Acalabrutinib (ACP-196)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Rituximab Plus Idelalisib or Bendamustine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idelalisib</intervention_name>
    <arm_group_label>Rituximab Plus Idelalisib or Bendamustine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <arm_group_label>Rituximab Plus Idelalisib or Bendamustine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ≥ 18 years of age.

          -  ECOG performance status of 0 to 2.

          -  Received ≥ 1 prior systemic therapies for CLL.

          -  Diagnosis of CLL - CD-20 positive, and meeting published criteria (Hallek, 2008).

          -  Active disease meeting ≥ 1 of the IWCLL 2008 criteria for requiring treatment.

          -  Meet the following laboratory parameters:

               -  ANC ≥ 750 cells/μL or ≥ 500 cells/μL in subjects with documented bone marrow
                  involvement, and independent of growth factor support 7 days before assessment.

               -  Platelet count ≥ 50,000 cells/μL or ≥ 30,000 cells/μL in subjects with documented
                  bone marrow involvement, and without transfusion support 7 days before
                  assessment.

               -  AST and ALT ≤ 2.0 x upper limit of normal

               -  Total bilirubin ≤ 1.5 x ULN.

               -  Estimated creatinine clearance of ≥ 30 mL/min

        Exclusion Criteria:

          -  Known prolymphocytic leukemia or history of, or currently suspected, Richter's
             syndrome. Known CNS lymphoma or leukemia.

          -  Prior exposure to a BCL-2 inhibitor or B-cell receptor inhibitor.

          -  Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura.

          -  Received any chemotherapy, external beam radiation therapy, anticancer antibodies, or
             investigational drug within 30 days before first dose of study drug.

          -  Prior radio- or toxin-conjugated antibody therapy.

          -  Major surgery within 30 days of first dose of study drug.

          -  Prior malignancy, except for adequately treated lentigo maligna melanoma,
             non-melanomatous skin cancer, carcinoma in situ or other malignancy treated with no
             evidence of active disease &gt; 2 years before Screening and at low risk for recurrence.

          -  Significant cardiovascular disease within 6 months of screening.

          -  Known history of infection with HIV, or any uncontrolled active systemic infection.

          -  Active CMV infection.

          -  Serologic status reflecting active hepatitis B or C infection.

          -  History of or ongoing drug-induced pneumonitis.

          -  Malabsorption syndrome, or other condition that would impair absorption of oral study
             medication.

          -  Received a live virus vaccination within 28 days of first dose of study drug.

          -  History of stroke or intracranial hemorrhage within 6 months before first dose of
             study drug.

          -  History of bleeding diathesis.

          -  Requires or receiving anticoagulation with warfarin or equivalent vitamin K
             antagonists within 7 days of first dose of study drug.

          -  Requires treatment with a strong CYP3A inhibitor/inducer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priti Patel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Acerta Pharma BV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie Stewart</last_name>
    <phone>6505912800</phone>
    <phone_ext>167</phone_ext>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeannine Madere</last_name>
    <phone>6505912800</phone>
    <phone_ext>231</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ventura County Hematology-Oncology Specialists</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology Hematology Associates, Ltd</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Physicians Clinic of Iowa, P.C.</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montgomery Cancer Center</name>
      <address>
        <city>Mount Sterling</city>
        <state>Kentucky</state>
        <zip>40353</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Coborn Cancer Center</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nebraska Hematology-Oncology</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Jersey Hematology / Oncology Associates</name>
      <address>
        <city>Bricktown</city>
        <state>New Jersey</state>
        <zip>08724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Rockland</name>
      <address>
        <city>Nyack</city>
        <state>New York</state>
        <zip>10960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Health</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78665</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2016</study_first_submitted>
  <study_first_submitted_qc>November 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2016</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL</keyword>
  <keyword>BTK</keyword>
  <keyword>Bruton Tyrosine Kinase</keyword>
  <keyword>acalabrutinib</keyword>
  <keyword>ACP-196</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idelalisib</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

